安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens
- Iterum Therapeutics Receives U. S. FDA Approval of ORLYNVAH™ (Oral . . .
Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U S Food and Drug
- Iterum Therapeutics Announces Positive Topline Results from its Phase 3 . . .
Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications For more information, please visit www iterumtx com
- Our Company :: Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc: Headquartered in Dublin, Ireland, we are dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world
- Investor Relations :: Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world
- Iterum Therapeutics Announces Completion of Enrollment in its REASSURE . . .
Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications, including uUTI For more information, please visit http: www iterumtx com
- Iterum Therapeutics Announces Partnership for Commercialization . . .
Iterum is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world
- Iterum Therapeutics Reports First Quarter 2025 Financial Results
DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31
|
|
|